Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
on 21 February 2022, the Company announced it successfully completed the integration of its first personalised dosing tool for docetaxel in prostate cancer into the DoseMeRx software platform owned by US corporation Tabula Rasa Healthcare Inc ("TRHC"). TRHC recently announced that it intends to sell its DoseMeRx business, however, Physiomics continues to work with DoseMeRx during the sale process and looks forward to further developing the collaboration with DoseMeRx's new owners as and when the transaction is completed. In the meantime, following positive feedback on the initial integration, Physiomics and DoseMeRx are exploring further development of the personalised dosing tool in other cancer indications where the two companies believe there may be more significant commercial potential.
Jim Millen (CEO ) Joined in 2016 with 15yrs experience across blue chip globals and smaller UK companies. Previously had a Business Development role at Glax
Clients include :
Sareum (AIM listed)
Valirax (AIM listed)
Cellcentric
Merck
Numab (Swiss pharma)
Astella (Japanese multinational)
Cellcentric
Bicycle ( $500mln NASDAQ)
Tabula Rasa Healthcare ( $1.4 bln NASDAQ)
New Boston (USA) company March 2022 who have just raised $45mln
Servier France HQ global company with €3bln revenues
pleased to announce that it has signed new agreements with existing client, Merck KGaA ("Merck"), with an aggregate value of £300,000. These projects are expected to be completed over the course of the next six months and will span a range of drug targets and treatment types in both pre-clinical and clinical settings with a particular focus on DNA damage and repair ("DDR") agents.
As has been the case in 2021, the board of Physiomics (the "Board") expects further contracts to be signed with Merck over the course of 2022.
Dr Jim Millen, CEO of Physiomics, said: "We're delighted that we continue to have a strong relationship with Merck and that our predictive modelling capabilities are, we believe, proving highly useful in the design of a number of their key clinical programs. In our view, there is no other company with Physiomics' experience in the field of DDR modelling and with every new project we further develop our capabilities in this field. These contracts provide a great platform for our work with Merck in 2022 and we expect further projects to be signed over the course of the full year."
Yes keeping an eye on that sale, no whispers found anywhere of who could be buying DoseMeRX.
And for clarity and so no mis-information can be spread, probably Monday, there will will 2 x 90k ish trades go thru very close together. They will look like sells, they are indeed my B&I which will be added to my pot of over 900k shares, just in case any of the usual protagonists mis -read the trade data & try and spin it a different way.
There was a signed letter of intent for the sale but looks like it's still under some NDA...
Kiddlington Worth keeping tabs on this sale?
Q: The tie-up with Tabula Rasa and their DosemeRx platform was considered to be a potential game changer for Physiomics. Now that Tabula Rasa have advised the market that they are selling their interest in DosemeRx does this in any way diminish this commercial potential
The answer to this was also covered during the main presentation however just to say that DoseMeRx remains interested in working with Physiomics and we are actively looking at other opportunities to commercialise our personalised dosing tool and platform. Physiomics has no knowledge of who might be interested in buying DoseMeRx but believes there is a reasonable chance that whoever it is, is going to be at least as interested in personalised dosing as DoseMeRx’s current owner.
This buy out is currently going on and once new buyer comes then PYC will be able to agree commercial terms with new purchaser
*2021 sorry lol
Clients results for second quarter:
https://www.merck.com/stories/our-second-quarter-2021-financial-results/
Merck announced second-quarter 2021 sales from continuing operations (excluding Organon) of $11.4 billion, 22% above second-quarter 2020. Excluding the impact from foreign exchange, sales grew 19%.
https://investors.bicycletherapeutics.com/news-releases/news-release-details/bicycle-therapeutics-reports-second-quarter-2021-
Collaboration revenues 6 months ended June 30
2020: $2,700
2021: $3,593
https://www.lse.co.uk/rns/PYC/final-results-setufg8l0ipbdl4.html
Total income (revenue and grant income) decreased 13% to £730,899 (2020: £841,649), the third highest in the Company's history despite a full year of the impact of Covid-19
Snippet from 2031 results….
the Company has been able to:
· Support big pharma companies in developing evidence based dose reduction algorithms to optimise the balance of efficacy and toxicity. These algorithms have the potential to be used in the pivotal studies of significant big pharma pipeline drugs
· Predict the clinical efficacy of cancer regimens amongst patients with various specific genetic settings, based on extensive preclinical modelling and then translation of these settings to man
· Use modelling to generate hypotheses as to the mechanism of action of client assets and predict/ explain why they may have a competitive advantage over other marketed drugs with the same targets
· Support and inform first in man dosing based on predictions of biologically effective dose from computer models
after yesterdays announcement by Sareum: https://www.investegate.co.uk/sareum-holdings-plc--sar-/rns/sareum-notes-acquisition-of-sierra-oncology-by-gsk/202204131600173162I/ There is a historical link between PYC business and SAR https://www.physiomics.co.uk/company-update/ dated (Dec 2016) https://www.physiomics.co.uk/wp-content/uploads/2019/04/2017-1-11-Company-Update-2.pdf
The work was done is association with CRT and ProNAi, who then changed their name to Sierra. https://www.prnewswire.com/news-releases/pronai-relaunched-as-sierra-oncology-to-advance-ddr-based-cancer-drugs-610090235.html Drug was called PNT737, then to SRA737
Well it all sounds good, a strong pipeline, but the interim results also showed the operating expenses have increased so firstly what did it cost them to get that pipeline, and secondly can they sustain it, because they haven't been particularly consistent.
The £1mln raised May 2020 remained almost untouched UNTIl they decided to spend for EXPANSION of staff and MARKETING etc
The increased cash was 3+ new staff and increased marketing!
I.e PLANNED spending !!
Q: Please say a few words on the current pipeline?
The pipeline is genuinely the strongest it’s ever been. For the first time, we’ve really been able to quantify that by disclosing that we have contracted revenue of over £460,000 for this half that we’re in now. We’ve never been able to say that before. We’ve never had that degree of visibility for the next five months. And obviously that’s just the revenues that we have signed up at this point in time.
Above these contracted revenues in the pyramid of Business Development we have a number of contracts that are in discussion, one of which is with another big pharma Company. If we can clinch that one, that is another very exciting opportunity and could be a big step forward for the Company. But it’s not the only opportunity. We now have a more rigorous process for categorising the different opportunities thanks to our new BD lead. While this isn’t something that I can explain in a few words, I can assure you that at every stage within that BD funnel we now looking stronger than I think we ever have done before.
Cash and cash equivalents of £794k at 31 December 2021 (31 December 2020: £1.15m)
356k decrease in cash in 1 year.
annual net cash outflow a mere £34k for this last year
Total income was the highest first half income ever recorded by Physiomics and slightly ahead of the six-month comparable prior period ended 31 December 2020. Operating losses of £170k were just £38k greater than those of the comparable prior period despite a significant increase in marketing activities, including the hiring of the Company's first Head of Business Development. The Company finished the half with a strong balance sheet showing shareholder funds of £1.08m at 31 December 2021 (compared with £1.29m at 31 December 2020) of which £794k were cash and cash equivalents
https://www.investegate.co.uk/sareum-holdings-plc--sar-/rns/sareum-notes-acquisition-of-sierra-oncology-by-gsk/202204131600173162I/ RNS just landed… interesting we had involvement in this?
I like this snippet
In addition to the areas noted above, the Company is actively considering how it could use its extensive capabilities in modelling, simulation, data analysis and AI techniques, to develop further innovative assets in collaboration with other partners. The Company is particularly focused on fields such as AI-enabled drug discovery/development and cancer diagnostics. Further information on this initiative will be provided as progress is made.
Q: Can we say how long we’ve been in discussion with the potential new big pharmaceutical client?
We’ve been in discussion with them for over 12 months, and that is common for big pharma clients.
Large pharma been in discussions 12 months prior to March 2022 interims news due